The biomarker NT-proBNP was as predictive as a traditional multivariable risk model for both death and CV events in T2DM patients with CVD and/or CKD.
The SGLT2 inhibitor dapagliflozin has been granted Breakthrough Therapy Designation by the FDA for patients with chronic kidney disease, with and without T2DM.
This subanalysis of the ODYSSEY OUTCOME trial evaluated whether the effects of alirocumab, compared to placebo, on MACE and all-cause death are influenced by renal function in patients with recent ACS.
This substudy of the PARAGON-HF trial demonstrated that in HFpEF patients, sacubitril/valsartan reduced the risk of a composite of renal outcomes and attenuated decline in kidney function compared to valsartan alone.
ESC 2020 Ticagrelor monotherapy after 3 months DAPT reduced risk of bleeding without increasing rate of thrombotic events compared to ticagrelor plus aspirin in high risk CDK patients undergoing PCI.
Prof. De Boer explains that the effects of SGLT2 inhibitors go beyond diuresis and that SGLT2 inhibitors are a new foundation in CV risk management, spanning from T2DM to heart failure patients.
ESC 2020 After the DAPA-CKD trial was stopped due to overwhelming results, analysis showed 39% reduction of the primary endpoint with dapagliflozin compared to placebo in CKD patients.
ESC 2020 The DAPA-CKD trial showed that dapagliflozin significantly reduced the risk of kidney failure, CV death or HF hospitalization, and all-cause mortality in patients with CKD, with and without T2DM, compared to placebo.
In this e-learning course, participants will learn about diabetic kidney disease and how to manage patients with DKD. Member registration (free) is needed to enroll in this course.
This e-learning course focusses on effects of SGLT2 inhibitors on outcomes in CKD patients and (potential) mechanisms of SGLT2 inhibitors. Member registration (free) is needed to enroll in this course.
The SGLT2 inhibitor dapagliflozin reduced the primary endpoint and all secondary endpoints in the phase 3 DAPA-CKD trial, that enrolled CKD patients with and without T2DM.
T2DM patients who developed HF alone or in combination with stroke, CKD or PAD had the highest 5-year risk of death and the greatest decrease in lifespan when compared with development of other CV and renal diseases.